Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p>Efforts are under way to improve the efficacy of subunit malaria vaccines through assessments of new adjuvants, vaccination platforms, and antigens. In this study, we further assessed the <jats:named-content content-type="genus-species">Plasmodium falciparum</jats:named-content> antigen upregulated in infective sporozoites 3 (PfUIS3) as a vaccine candidate. PfUIS3 was expressed in the viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in a prime-boost regimen. We previously demonstrated that this regimen could provide partial protection against challenge with chimeric <jats:named-content content-type="genus-species">P. berghei</jats:named-content> parasites expressing PfUIS3. We now show that ChAd63-MVA PfUIS3 can also provide partial cross-species protection against challenge with wild-type <jats:named-content content-type="genus-species">P. berghei</jats:named-content> parasites. We also show that PfUIS3-specific cellular memory responses could be recalled in human volunteers exposed to <jats:named-content content-type="genus-species">P. falciparum</jats:named-content> parasites in a controlled human malaria infection study. When ChAd63-MVA PfUIS3 was coadministered with the vaccine candidate <jats:named-content content-type="genus-species">P. falciparum</jats:named-content> thrombospondin-related adhesion protein (PfTRAP) expressed in the ChAd63-MVA system, there was no significant change in immunogenicity to either vaccine. However, when mice were challenged with double chimeric <jats:named-content content-type="genus-species">P. berghei</jats:named-content>-<jats:named-content content-type="genus-species">P. falciparum</jats:named-content> parasites expressing both PfUIS3 and PfTRAP, vaccine efficacy was improved to 100% sterile protection. This synergistic effect was evident only when the two vaccines were mixed and administered at the same site. We have therefore demonstrated that vaccination with PfUIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chimeric parasites expressing PfUIS3 as well as wild-type <jats:named-content content-type="genus-species">P. berghei</jats:named-content>; when this vaccine is combined with another partially protective regimen (ChAd63-MVA PfTRAP), complete protection is induced.</jats:p>

Original publication

DOI

10.1128/iai.00641-16

Type

Journal article

Journal

Infection and Immunity

Publisher

American Society for Microbiology

Publication Date

03/2017

Volume

85